# Guided internet-based treatment for anxiety and depression in Norwegian primary care: a randomized non-inferiority effectiveness trial

**Authors:** Marit Knapstad, Otto Robert Smith

PMC · DOI: 10.1016/j.invent.2026.100913 · 2026-01-25

## TL;DR

This study compared guided internet-based therapy with usual care for anxiety and depression in Norway, finding similar improvements but less therapist time with the internet-based approach.

## Contribution

The study evaluates the non-inferiority of guided internet-based therapy in a primary care setting, providing insights into its effectiveness and efficiency.

## Key findings

- Both guided internet-based therapy and usual care led to clinically significant symptom reductions in depression and anxiety.
- Guided internet-based therapy was not non-inferior to usual care for primary and several secondary outcomes.
- Guided internet-based therapy required about 46% less therapist time than usual care.

## Abstract

Meta-analyses suggest that therapist-guided internet-based cognitive behavioural therapy (iCBT) is as effective as face-to-face CBT for anxiety and depression, yet its non-inferiority in routine primary care settings is scarcely examined. We examined the non-inferiority of the therapist-guided program “Assisted self-help” (AS-iCBT) compared to treatment as usual within the Norwegian Prompt Mental Health Care (TAU-PMHC).

A pragmatic, parallel-group, randomized controlled non-inferiority trial with 1:2 (AS-iCBT: TAU-PMHC) allocation was conducted. Participants (n = 390, 37.4% of eligible) were adults considered for PMHC admission for anxiety and/or mild to moderate depression between October 2021, and December 2023. TAU-PMHC was predominantly individual face-to-face therapy (78%). Primary outcomes were change in symptoms of depression (PHQ-9) and anxiety (GAD-7) at six months follow-up. Symptom trajectories were analysed using latent growth curve models with robust maximum likelihood estimator (MLR), employing a non-inferiority margin of d > −0.30.

Both groups showed clinically significant reductions in PHQ-9 (dw: AS-iCBT = −1.15, TAU-PMHC = -1.26) and GAD-7 (dw: AS-iCBT = −0.92, TAU-PMHC = −1.11) at 6 months follow-up. However, AS-iCBT was not non-inferior to TAU-PMHC for primary outcomes (PHQ-9: db = −0.11 [95% CI -0.40; 0.19]; GAD-7: db = −0.19 [95% CI -0.43; 0.04]) and several secondary outcomes. Non-inferiority was demonstrated in client-rated but not therapist-rated alliance. AS-iCBT required approximately 46% less therapist time per client than TAU-PMHC.

AS-iCBT did not meet the pre-defined criteria for non-inferiority compared to usual PMHC care for most outcomes. Nevertheless, AS-iCBT showed potential as a resource-efficient treatment option, requiring less therapist time while achieving clinically significant improvements. Further research should focus on optimizing its implementation, particularly for anxiety-related conditions.

•Guided iCBT was compared to usual primary care for anxiety and depression.•Both treatments gave clinically significant improvements across outcomes.•Guided iCBT was not non-inferior on primary and several secondary outcomes.•Guided iCBT required approximately 46% less therapist time.•Client-rated therapeutic alliance in guided iCBT was non-inferior to usual care.

Guided iCBT was compared to usual primary care for anxiety and depression.

Both treatments gave clinically significant improvements across outcomes.

Guided iCBT was not non-inferior on primary and several secondary outcomes.

Guided iCBT required approximately 46% less therapist time.

Client-rated therapeutic alliance in guided iCBT was non-inferior to usual care.

## Linked entities

- **Diseases:** anxiety (MONDO:0005618), depression (MONDO:0002050)

## Full-text entities

- **Genes:** GAD1 (glutamate decarboxylase 1) [NCBI Gene 2571] {aka CPSQ1, DEE89, GAD, GAD-67, SCP}
- **Diseases:** anxiety (MESH:D001007), depression (MESH:D003866)
- **Chemicals:** TAU (MESH:C000609666)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12907875/full.md

---
Source: https://tomesphere.com/paper/PMC12907875